{"id":6340,"date":"2026-04-11T11:19:28","date_gmt":"2026-04-11T08:19:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=6340"},"modified":"2026-04-11T11:19:30","modified_gmt":"2026-04-11T08:19:30","slug":"investigational-new-drug-ind-clearance-for-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/investigational-new-drug-ind-clearance-for-duchenne-muscular-dystrophy\/","title":{"rendered":"Duchenne Kas Distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) Onay\u0131: S\u00fcre\u00e7, Denemeler ve Gelecek Tedaviler"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131na giden yol, modern ila\u00e7 geli\u015ftirmenin en kritik d\u00fczenleyici a\u015famalar\u0131ndan biridir.<\/strong> IND onay\u0131, gen terapilerinden ekzon atlama ila\u00e7lar\u0131na kadar deneysel tedavilerin laboratuvar ara\u015ft\u0131rmalar\u0131ndan insan klinik denemelerine ge\u00e7mesine olanak tan\u0131r. T\u0131bbi ihtiyac\u0131n b\u00fcy\u00fck \u00f6l\u00e7\u00fcde kar\u015f\u0131lanmad\u0131\u011f\u0131 Duchenne kas distrofisi (DMD) ba\u011flam\u0131nda, IND onay yollar\u0131, IND ba\u015fvurular\u0131 ve d\u00fczenleyici onaylar, tedaviye eri\u015fimin ve yenili\u011fin gelece\u011fini \u015fekillendiriyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi, distrofin eksikli\u011finden kaynaklanan ilerleyici kas dejenerasyonu ile karakterize edilen, X kromozomuna ba\u011fl\u0131 \u015fiddetli bir genetik hastal\u0131kt\u0131r. Gen terapileri ve ekzon atlama ila\u00e7lar\u0131 gibi son zamanlarda onaylanan tedavilere ra\u011fmen, hala kesin bir tedavisi bulunmamaktad\u0131r. <strong>Bu nedenle, Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131, hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmay\u0131, durdurmay\u0131 veya potansiyel olarak tersine \u00e7evirmeyi ama\u00e7layan yeni nesil tedavilere a\u00e7\u0131lan kap\u0131 olmaya devam etmektedir.<\/strong><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-an-investigational-new-drug-ind\">Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) Nedir?<\/a><\/li><li><a href=\"#why-ind-clearance-matters-in-duchenne-muscular-dystrophy\">Duchenne Musk\u00fcler Distrofisinde IND Onay\u0131 Neden \u00d6nemlidir?<\/a><ul><\/ul><\/li><li><a href=\"#the-ind-application-process-for-dmd-therapies\">DMD Terapileri i\u00e7in IND Ba\u015fvuru S\u00fcreci<\/a><ul><\/ul><\/li><li><a href=\"#types-of-ind-applications-relevant-to-dmd\">DMD ile \u0130lgili IND Ba\u015fvuru T\u00fcrleri<\/a><\/li><li><a href=\"#clinical-trial-phases-after-ind-clearance\">IND Onay\u0131 Sonras\u0131nda Klinik Ara\u015ft\u0131rma A\u015famalar\u0131<\/a><ul><\/ul><\/li><li><a href=\"#recent-ind-clearances-in-duchenne-muscular-dystrophy\">Duchenne Kas Distrofisi ile \u0130lgili Son IND Onaylar\u0131<\/a><ul><\/ul><\/li><li><a href=\"#types-of-therapies-advancing-through-ind-in-dmd\">DMD&#039;de IND A\u015famas\u0131nda \u0130lerleyen Terapi T\u00fcrleri<\/a><ul><\/ul><\/li><li><a href=\"#regulatory-designations-supporting-ind-programs\">IND Programlar\u0131n\u0131 Destekleyen D\u00fczenleyici Atamalar<\/a><\/li><li><a href=\"#challenges-in-ind-clearance-for-duchenne-muscular-dystrophy\">Duchenne Kas Distrofisi \u0130\u00e7in IND Onay\u0131nda Kar\u015f\u0131la\u015f\u0131lan Zorluklar<\/a><ul><\/ul><\/li><li><a href=\"#ethical-considerations-in-ind-trials-for-dmd\">DMD i\u00e7in IND Klinik \u00c7al\u0131\u015fmalar\u0131nda Etik Hususlar<\/a><\/li><li><a href=\"#future-outlook-ind-and-the-next-generation-of-dmd-therapies\">Gelece\u011fe Bak\u0131\u015f: IND ve Yeni Nesil DMD Terapileri<\/a><\/li><li><a href=\"#frequently-asked-questions-faq\">S\u0131k\u00e7a Sorulan Sorular (SSS)<\/a><ul><li><a href=\"#faq-question-1775727500437\">Duchenne kas distrofisi i\u00e7in IND onay\u0131 nedir?<\/a><\/li><li><a href=\"#faq-question-1775727515941\">DMD hastalar\u0131 i\u00e7in IND onay\u0131n\u0131n \u00f6nemi nedir?<\/a><\/li><li><a href=\"#faq-question-1775727522877\">IND onay\u0131 almak ne kadar s\u00fcrer?<\/a><\/li><li><a href=\"#faq-question-1775727558323\">IND onay\u0131 verildikten sonra ne olur?<\/a><\/li><li><a href=\"#faq-question-1775727593040\">\u00c7ocu\u011fum IND onay\u0131 sonras\u0131nda tedaviye eri\u015febilir mi?<\/a><\/li><li><a href=\"#faq-question-1775727649350\">IND onayl\u0131 tedaviler g\u00fcvenli mi?<\/a><\/li><li><a href=\"#faq-question-1775727682964\">DMD&#039;de hangi terapi t\u00fcrleri IND onay\u0131 almaktad\u0131r?<\/a><\/li><li><a href=\"#faq-question-1775727719710\">Aileler DMD i\u00e7in IND klinik ara\u015ft\u0131rmalar\u0131n\u0131 nas\u0131l bulabilir?<\/a><\/li><li><a href=\"#faq-question-1775727755790\">IND onay\u0131, tedavinin onaylanaca\u011f\u0131 anlam\u0131na m\u0131 geliyor?<\/a><\/li><li><a href=\"#faq-question-1775727770304\">IND klinik ara\u015ft\u0131rmas\u0131na kat\u0131lman\u0131n riskleri nelerdir?<\/a><\/li><\/ul><\/li><li><a href=\"#final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-an-investigational-new-drug-ind\">Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND), ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) taraf\u0131ndan verilen ve bir ila\u00e7 veya biyoteknoloji \u015firketinin yeni bir tedaviyi insanlarda test etmeye ba\u015flamas\u0131na izin veren bir d\u00fczenleyici yetkilendirmedir (FDA).<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ara\u015ft\u0131rmalar ba\u015flamadan \u00f6nce, sponsorlar\u0131n a\u015fa\u011f\u0131daki bilgileri i\u00e7eren bir IND ba\u015fvurusu sunmalar\u0131 gerekmektedir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Klinik \u00f6ncesi veriler (hayvan g\u00fcvenli\u011fi ve farmakoloji)<\/li>\n\n\n\n<li>\u00dcretim detaylar\u0131<\/li>\n\n\n\n<li>Klinik ara\u015ft\u0131rma protokolleri<\/li>\n\n\n\n<li>Ara\u015ft\u0131rmac\u0131 nitelikleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">FDA, IND'yi 30 g\u00fcn i\u00e7inde inceler. Herhangi bir itiraz gelmezse, klinik denemeye devam edebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu s\u00fcre\u00e7, Duchenne kas distrofisi i\u00e7in deneysel tedavilerin hastalara uygulanmadan \u00f6nce minimum g\u00fcvenlik standartlar\u0131n\u0131 kar\u015f\u0131lamas\u0131n\u0131 sa\u011flamak i\u00e7in elzemdir.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"409\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1024x409.png\" alt=\"Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) Ba\u015fvurusu\" class=\"wp-image-7481\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1024x409.png 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-300x120.png 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-768x307.png 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1536x613.png 1536w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-2048x818.png 2048w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-18x7.png 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1052x420.png 1052w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-150x60.png 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-696x278.png 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1068x426.png 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-1-1-1920x767.png 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-ind-clearance-matters-in-duchenne-muscular-dystrophy\">Duchenne Musk\u00fcler Distrofisinde IND Onay\u0131 Neden \u00d6nemlidir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131n\u0131n \u00f6nemi k\u00fc\u00e7\u00fcmsenemez.<\/strong> DMD h\u0131zla ilerleyen bir hastal\u0131kt\u0131r ve erken m\u00fcdahale hayati \u00f6nem ta\u015f\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"key-reasons-ind-clearance-is-vital\">IND onay\u0131n\u0131n hayati \u00f6nem ta\u015f\u0131mas\u0131n\u0131n ba\u015fl\u0131ca nedenleri:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u0130nsanlar \u00fczerinde ilk denemelerin yap\u0131lmas\u0131n\u0131 sa\u011flar<\/strong><\/li>\n\n\n\n<li><strong>Klinik \u00f6ncesi ara\u015ft\u0131rmalar\u0131 do\u011frular<\/strong><\/li>\n\n\n\n<li><strong>Nadir hastal\u0131klar alan\u0131nda inovasyonu h\u0131zland\u0131r\u0131r<\/strong><\/li>\n\n\n\n<li><strong>Hayat de\u011fi\u015ftirebilecek tedavilere erken eri\u015fim sa\u011flar<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Son veriler, d\u00fcnya genelinde binlerce \u00e7ocu\u011fun DMD&#039;den etkilendi\u011fini ve erken yeti\u015fkinlik d\u00f6neminde \u00f6nemli oranda hastal\u0131k ve \u00f6l\u00fcm oranlar\u0131na yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-ind-application-process-for-dmd-therapies\">DMD Terapileri i\u00e7in IND Ba\u015fvuru S\u00fcreci<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"preclinical-phase\">Klinik \u00d6ncesi A\u015fama<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 ba\u015fvurusunda bulunmadan \u00f6nce, ara\u015ft\u0131rmac\u0131lar\u0131n a\u015fa\u011f\u0131daki ad\u0131mlar\u0131 tamamlamalar\u0131 gerekmektedir:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Toksikoloji \u00e7al\u0131\u015fmalar\u0131<\/li>\n\n\n\n<li>Farmakokinetik analiz<\/li>\n\n\n\n<li>Hayvan modellerinde kavramsal etkinli\u011fin kan\u0131tlanmas\u0131<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"ind-submission\">IND Ba\u015fvurusu<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">IND dosyas\u0131nda \u015funlar yer almaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kimya, \u00dcretim ve Kontroller (CMC)<\/li>\n\n\n\n<li>Klinik protokoller (Faz 1 tasar\u0131m\u0131)<\/li>\n\n\n\n<li>Ara\u015ft\u0131rmac\u0131 bro\u015f\u00fcrleri<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"fda-review\">FDA \u0130ncelemesi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA a\u015fa\u011f\u0131daki hususlar\u0131 de\u011ferlendirir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Risk ve fayda kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/li>\n\n\n\n<li>Deneme tasar\u0131m\u0131 g\u00fcvenli\u011fi<\/li>\n\n\n\n<li>Etik hususlar<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Onaylan\u0131rsa, tedavi klinik denemelere girer.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"types-of-ind-applications-relevant-to-dmd\">DMD ile \u0130lgili IND Ba\u015fvuru T\u00fcrleri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ba\u011flama ba\u011fl\u0131 olarak farkl\u0131 IND yollar\u0131 mevcuttur:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ticari IND&#039;ler<\/strong> \u2013 \u0130la\u00e7 geli\u015ftirme s\u00fcre\u00e7leri i\u00e7in<\/li>\n\n\n\n<li><strong>Ara\u015ft\u0131rmac\u0131 IND&#039;leri<\/strong> \u2013 Akademisyenler taraf\u0131ndan y\u00fcr\u00fct\u00fclen ara\u015ft\u0131rma<\/li>\n\n\n\n<li><strong>Geni\u015fletilmi\u015f Eri\u015fim IND&#039;leri<\/strong> \u2013 A\u011f\u0131r vakalarda merhamet ama\u00e7l\u0131 kullan\u0131m<\/li>\n\n\n\n<li><strong>Tedavi IND&#039;leri<\/strong> \u2013 Tam onaydan \u00f6nce erken eri\u015fim<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu yollar, ya\u015fam\u0131 tehdit eden do\u011fas\u0131 nedeniyle Duchenne kas distrofisi i\u00e7in \u00f6zellikle \u00f6nemlidir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"clinical-trial-phases-after-ind-clearance\">IND Onay\u0131 Sonras\u0131nda Klinik Ara\u015ft\u0131rma A\u015famalar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 verildikten sonra, klinik denemeler a\u015famalar halinde ilerler:<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"phase-1-safety\">A\u015fama 1: G\u00fcvenlik<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>K\u00fc\u00e7\u00fck hasta gruplar\u0131<\/li>\n\n\n\n<li>Tolerans d\u00fczeyine odaklan\u0131r<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"phase-2-efficacy-and-dosing\">Faz 2: Etkinlik ve Dozaj<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Daha b\u00fcy\u00fck gruplar<\/li>\n\n\n\n<li>Etkinli\u011fe dair ilk i\u015faretler<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"phase-3-confirmation\">A\u015fama 3: Onaylama<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>B\u00fcy\u00fck \u00f6l\u00e7ekli denemeler<\/li>\n\n\n\n<li>Standart bak\u0131mla kar\u015f\u0131la\u015ft\u0131rma<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"phase-4-post-marketing\">4. A\u015fama: Pazarlama Sonras\u0131<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Uzun s\u00fcreli izleme<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Her a\u015fama, tam d\u00fczenleyici onay i\u00e7in gerekli kan\u0131tlar\u0131 olu\u015fturur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/drug-development-phases\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u0130la\u00e7 Geli\u015ftirmedeki 5 Faz\u0131 Ke\u015ffedin<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"recent-ind-clearances-in-duchenne-muscular-dystrophy\">Duchenne Kas Distrofisi ile \u0130lgili Son IND Onaylar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 s\u00fcreci h\u0131zla geli\u015fiyor.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"example-ryoncil-remestemcel-l\">\u00d6rnek: Ryoncil (Remestemcel-L)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kay\u0131t denemesi i\u00e7in IND onay\u0131 verildi<\/li>\n\n\n\n<li>DMD'deki iltihab\u0131 hedef al\u0131r<\/li>\n\n\n\n<li>Kas fonksiyonunu korumaya odaklan\u0131r<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu tedavi, mezenkimal stromal h\u00fccrelere dayanmaktad\u0131r ve kas dokusundaki iltihaplanma hasar\u0131n\u0131 azaltmay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"example-pbgene-dmd-gene-editing-therapy\">\u00d6rnek: PBGENE-DMD Gen D\u00fczenleme Terapisi<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IND onay\u0131 ve H\u0131zl\u0131 Takip stat\u00fcs\u00fc kazand\u0131<\/li>\n\n\n\n<li>Genom d\u00fczenleme y\u00f6ntemini kullanarak distrofin \u00fcretimini geri kazand\u0131r\u0131yor<\/li>\n\n\n\n<li>DMD hastalar\u0131n\u0131n 'a kadar olan k\u0131sm\u0131n\u0131 kaps\u0131yor<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"ongoing-clinical-trials\">Devam Eden Klinik Ara\u015ft\u0131rmalar<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7e\u015fitli deneysel tedaviler IND onay\u0131 s\u00fcrecinde ilerleme kaydediyor:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ENTR-601-44 (ekzon atlama)<\/li>\n\n\n\n<li>INS1201 (yeni da\u011f\u0131t\u0131m yakla\u015f\u0131mlar\u0131)<\/li>\n\n\n\n<li>SGT-003 gen terapisi<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"types-of-therapies-advancing-through-ind-in-dmd\">DMD&#039;de IND A\u015famas\u0131nda \u0130lerleyen Terapi T\u00fcrleri<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-gene-therapy\">1. Gen Terapisi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Gen terapilerinin amac\u0131, i\u015flevsel distrofin genlerini v\u00fccuda kazand\u0131rmakt\u0131r.<br>\u00d6rnek: Mikro-distrofin tedavileri \u015fimdiden umut vaat ediyor ancak de\u011ferlendirme a\u015famas\u0131nda bulunuyor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-exon-skipping\">2. Ekzon Atlama<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Okuma \u00e7er\u00e7evesini eski haline getirmek i\u00e7in belirli mutasyonlar\u0131 hedefler.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"3-gene-editing-crispr-like\">3. Gen D\u00fczenleme (CRISPR benzeri)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Genetik kusurlar\u0131n kal\u0131c\u0131 olarak d\u00fczeltilmesi.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"4-cell-therapy\">4. H\u00fccre Terapisi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">K\u00f6k h\u00fccreleri kullanarak kas dokusunu yeniler.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"5-anti-inflammatory-approaches\">5. \u0130ltihap \u00d6nleyici Yakla\u015f\u0131mlar<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130ltihaplanma gibi ikincil hastal\u0131k mekanizmalar\u0131n\u0131 ele al\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"regulatory-designations-supporting-ind-programs\">IND Programlar\u0131n\u0131 Destekleyen D\u00fczenleyici Atamalar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay s\u00fcrecini h\u0131zland\u0131rmak amac\u0131yla FDA \u015fu avantajlar\u0131 sunmaktad\u0131r:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>H\u0131zl\u0131 Yol atamas\u0131<\/li>\n\n\n\n<li>Yetim \u0130la\u00e7 stat\u00fcs\u00fc<\/li>\n\n\n\n<li>\u00c7\u0131\u011f\u0131r A\u00e7an Terapi unvan\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu programlar geli\u015ftirme s\u00fcrelerini k\u0131salt\u0131r ve d\u00fczenleyici kurumlarla etkile\u015fimi kolayla\u015ft\u0131r\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"challenges-in-ind-clearance-for-duchenne-muscular-dystrophy\">Duchenne Kas Distrofisi \u0130\u00e7in IND Onay\u0131nda Kar\u015f\u0131la\u015f\u0131lan Zorluklar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lerleme kaydedilmesine ra\u011fmen, baz\u0131 engeller h\u00e2l\u00e2 mevcuttur:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"scientific-challenges\">Bilimsel Zorluklar<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Genetik heterojenlik<\/li>\n\n\n\n<li>S\u0131n\u0131rl\u0131 hayvan modeli \u00f6ng\u00f6r\u00fclebilirli\u011fi<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"regulatory-challenges\">D\u00fczenleyici Zorluklar<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Y\u00fcksek g\u00fcvenlik standartlar\u0131<\/li>\n\n\n\n<li>Karma\u015f\u0131k deneme sonu\u00e7 noktalar\u0131<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"economic-challenges\">Ekonomik Zorluklar<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Son derece y\u00fcksek geli\u015ftirme maliyetleri<\/li>\n\n\n\n<li>S\u0131n\u0131rl\u0131 hasta pop\u00fclasyonlar\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Onaylanm\u0131\u015f tedaviler bile \u00e7o\u011fu zaman eri\u015filebilirlik ve geri \u00f6deme sorunlar\u0131yla kar\u015f\u0131 kar\u015f\u0131ya kalmaktad\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ethical-considerations-in-ind-trials-for-dmd\">DMD i\u00e7in IND Klinik \u00c7al\u0131\u015fmalar\u0131nda Etik Hususlar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 s\u00fcrecinde etik kurallar merkezi bir rol oynamaktad\u0131r:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pediatrik hasta kat\u0131l\u0131m\u0131<\/li>\n\n\n\n<li>Bilgilendirilmi\u015f onam\u0131n karma\u015f\u0131kl\u0131klar\u0131<\/li>\n\n\n\n<li>Risk-fayda belirsizli\u011fi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aileler, erken a\u015fama klinik ara\u015ft\u0131rmalara kat\u0131l\u0131rken genellikle zor kararlarla kar\u015f\u0131 kar\u015f\u0131ya kal\u0131rlar.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"future-outlook-ind-and-the-next-generation-of-dmd-therapies\">Gelece\u011fe Bak\u0131\u015f: IND ve Yeni Nesil DMD Terapileri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131n\u0131n gelece\u011fi, geli\u015fmekte olan teknolojilere yak\u0131ndan ba\u011fl\u0131d\u0131r:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CRISPR tabanl\u0131 gen d\u00fczenleme<\/li>\n\n\n\n<li>RNA tabanl\u0131 terap\u00f6tikler<\/li>\n\n\n\n<li>Kombinasyon tedavileri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00fczenleyici \u00e7er\u00e7eveler geli\u015ftik\u00e7e, IND onay s\u00fcre\u00e7leri daha h\u0131zl\u0131 ve daha uyarlanabilir hale gelebilir.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"683\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-683x1024.png\" alt=\"Duchenne Kas Distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) Onay\u0131: S\u00fcre\u00e7, Denemeler ve Gelecek Tedaviler\" class=\"wp-image-7463\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-683x1024.png 683w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-200x300.png 200w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-768x1152.png 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-8x12.png 8w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-280x420.png 280w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-150x225.png 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-300x450.png 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance-696x1044.png 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2026\/04\/Investigational-New-Drug-IND-Clearance.png 1024w\" sizes=\"auto, (max-width: 683px) 100vw, 683px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions-faq\">S\u0131k\u00e7a Sorulan Sorular (SSS)<\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1775727500437\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Duchenne kas distrofisi i\u00e7in IND onay\u0131 nedir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131, yeni bir deneysel tedavinin insan klinik \u00e7al\u0131\u015fmalar\u0131nda test edilmesine olanak tan\u0131yan FDA yetkilendirmesidir. Bu onay, klinik \u00f6ncesi verilerin (laboratuvar ve hayvan \u00e7al\u0131\u015fmalar\u0131) hastalarda testlere ba\u015flamak i\u00e7in yeterli g\u00fcvenli\u011fi g\u00f6sterdi\u011fini do\u011frular. Bu ad\u0131m, gen terapisi veya ekzon atlama gibi herhangi bir yeni DMD tedavisinin \u00e7ocuklarda de\u011ferlendirilmesinden \u00f6nce \u00e7ok \u00f6nemlidir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727515941\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">DMD hastalar\u0131 i\u00e7in IND onay\u0131n\u0131n \u00f6nemi nedir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>IND onay\u0131, hen\u00fcz onaylanmam\u0131\u015f yeni tedavilere eri\u015fimi sa\u011flad\u0131\u011f\u0131 i\u00e7in kritik \u00f6neme sahiptir. Duchenne kas distrofisinden etkilenen aileler i\u00e7in, hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilecek veya kas fonksiyonunu iyile\u015ftirebilecek en son teknolojiye sahip tedavilerden yararlanma konusunda ilk ger\u00e7ek f\u0131rsat\u0131 temsil eder. IND onay\u0131 olmadan, klinik denemeler yasal olarak ba\u015flat\u0131lamaz.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727522877\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">IND onay\u0131 almak ne kadar s\u00fcrer?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>FDA, genellikle bir IND ba\u015fvurusunu 30 g\u00fcn i\u00e7inde inceler. Herhangi bir g\u00fcvenlik endi\u015fesi tespit edilmezse, \u00e7al\u0131\u015fma devam edebilir. Bununla birlikte, haz\u0131rl\u0131k a\u015famas\u0131 (klinik \u00f6ncesi \u00e7al\u0131\u015fmalar, \u00fcretim ve dok\u00fcmantasyon) ba\u015fvuru \u00f6ncesinde birka\u00e7 y\u0131l s\u00fcrebilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727558323\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">IND onay\u0131 verildikten sonra ne olur?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 al\u0131nd\u0131ktan sonra, tedavi klinik denemelere girer. Bu denemeler \u015fu a\u015famalardan ge\u00e7er:<\/p>\n<p>\u2022 A\u015fama 1: G\u00fcvenlik<br \/>\u2022 A\u015fama 2: Etkinlik ve dozaj<br \/>\u2022 A\u015fama 3: B\u00fcy\u00fck \u00f6l\u00e7ekli do\u011frulama<\/p>\n<p>Her a\u015fama, tam d\u00fczenleyici onay i\u00e7in gerekli verileri toplar.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727593040\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">\u00c7ocu\u011fum IND onay\u0131 sonras\u0131nda tedaviye eri\u015febilir mi?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Otomatik olarak de\u011fil. IND onay\u0131, klinik denemelerin ba\u015flamas\u0131na olanak tan\u0131r, ancak kat\u0131l\u0131m ya\u015f, mutasyon tipi ve hastal\u0131k evresi gibi uygunluk kriterlerine ba\u011fl\u0131d\u0131r. Baz\u0131 durumlarda, denemelere uygun olmayan \u00e7ocuklar i\u00e7in geni\u015fletilmi\u015f eri\u015fim veya insani kullan\u0131m programlar\u0131 mevcut olabilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727649350\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">IND onayl\u0131 tedaviler g\u00fcvenli mi?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>IND onay\u0131, tedavinin preklinik \u00e7al\u0131\u015fmalarda ilk g\u00fcvenlik kontrollerinden ge\u00e7ti\u011fi anlam\u0131na gelir, ancak tam g\u00fcvenlik veya etkinli\u011fi garanti etmez. Klinik \u00e7al\u0131\u015fmalar, riskleri ve faydalar\u0131 belirlemek i\u00e7in tasarlanm\u0131\u015ft\u0131r. Aileler, \u00e7al\u0131\u015fmaya kat\u0131lmadan \u00f6nce \u00e7al\u0131\u015fma protokollerini dikkatlice incelemeli ve uzmanlara dan\u0131\u015fmal\u0131d\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727682964\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">DMD&#039;de hangi terapi t\u00fcrleri IND onay\u0131 almaktad\u0131r?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131 alan tedaviler \u015funlard\u0131r:<\/p>\n<p>\u2022 Gen terapileri (mikro-distrofin iletimi)<br \/>\u2022 Ekzon atlama ila\u00e7lar\u0131<br \/>\u2022 Gen d\u00fczenleme yakla\u015f\u0131mlar\u0131 (CRISPR tabanl\u0131)<br \/>\u2022 H\u00fccre terapileri<br \/>\u2022 \u0130ltihap \u00f6nleyici tedaviler<\/p>\n<p>Her biri hastal\u0131\u011f\u0131n farkl\u0131 y\u00f6nlerini hedef al\u0131yor.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727719710\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Aileler DMD i\u00e7in IND klinik ara\u015ft\u0131rmalar\u0131n\u0131 nas\u0131l bulabilir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Aileler, aktif olan klinik ara\u015ft\u0131rmalar\u0131 \u015fu yollarla arayabilirler:<\/p>\n<p>\u2022 ClinicalTrials.gov<br \/>\u2022 N\u00f6rom\u00fcsk\u00fcler klinikler<br \/>\u2022 Hasta haklar\u0131 savunuculu\u011fu \u00f6rg\u00fctleri<\/p>\n<p>&quot;Duchenne kas distrofisi IND denemesi&quot; gibi anahtar kelimeler kullanmak, ilgili \u00e7al\u0131\u015fmalar\u0131 ve kat\u0131l\u0131mc\u0131 al\u0131m durumunu belirlemeye yard\u0131mc\u0131 olabilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727755790\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">IND onay\u0131, tedavinin onaylanaca\u011f\u0131 anlam\u0131na m\u0131 geliyor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p><strong>Hay\u0131r. IND onay\u0131 sadece ilk d\u00fczenleyici ad\u0131md\u0131r.<\/strong> Bir\u00e7ok tedavi, etkisizlik veya g\u00fcvenlik endi\u015feleri nedeniyle klinik denemeler s\u0131ras\u0131nda ba\u015far\u0131s\u0131z olur. Yaln\u0131zca t\u00fcm deneme a\u015famalar\u0131n\u0131 ba\u015far\u0131yla tamamlayan tedaviler, FDA onay\u0131 i\u00e7in ba\u015fvuruda bulunabilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1775727770304\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">IND klinik ara\u015ft\u0131rmas\u0131na kat\u0131lman\u0131n riskleri nelerdir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Klinik ara\u015ft\u0131rmalar belirsizlikler i\u00e7erir. Potansiyel riskler \u015funlard\u0131r:<\/p>\n<p>\u2022 Bilinmeyen yan etkiler<br \/>\u2022 S\u0131n\u0131rl\u0131 etkinlik<br \/>\u2022 S\u0131k hastane ziyaretleri ve testler<\/p>\n<p>Ancak, klinik \u00e7al\u0131\u015fmalar ayn\u0131 zamanda umut vadeden tedavilere erken eri\u015fim imkan\u0131 sunmakta ve t\u00fcm DMD hastalar\u0131 i\u00e7in ara\u015ft\u0131rmalar\u0131n ilerlemesine katk\u0131da bulunmaktad\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/www.fda.gov\/drugs\/types-applications\/investigational-new-drug-ind-application\" target=\"_blank\" rel=\"noreferrer noopener\">FDA IND<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi i\u00e7in Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) onay\u0131, inovasyonun \u00f6n\u00fcndeki kritik bir kap\u0131 olmaya devam etmektedir.<\/strong> Bu s\u00fcre\u00e7, hangi tedavilerin insan denemelerine ge\u00e7ece\u011fini ve hastalara ne kadar h\u0131zl\u0131 ula\u015faca\u011f\u0131n\u0131 belirler. Aileler i\u00e7in bu s\u00fcreci anlamak, bilin\u00e7li kararlar vermelerini sa\u011flar. <strong>Zorluklar devam etse de, gen terapisi ve ekzon atlama alan\u0131ndaki ilerleme h\u0131zlan\u0131yor.<\/strong> Nadir hastal\u0131klar\u0131 desteklemek i\u00e7in d\u00fczenleyici yollar da geli\u015fiyor. Her IND onay\u0131, DMD toplulu\u011funa yeni bir umut getiriyor. Bununla birlikte, eri\u015fim ve uygun fiyatl\u0131l\u0131k hala dikkat gerektiriyor. <strong>D\u00fczenleyiciler, ara\u015ft\u0131rmac\u0131lar ve savunucular aras\u0131ndaki i\u015fbirli\u011fi \u015fartt\u0131r.<\/strong> Bilgi sahibi olmak, se\u00e7enekler aras\u0131nda yol almak i\u00e7in \u00e7ok \u00f6nemlidir. DMD tedavisinin gelece\u011fi, IND \u00e7al\u0131\u015fmalar\u0131n\u0131n devam etmesine ba\u011fl\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/biologics-license-application-bla\/\" target=\"_blank\" rel=\"noreferrer noopener\">Biyolojik Lisans Ba\u015fvurusu (BLA): FDA Onay S\u00fcrecine \u0130li\u015fkin Eksiksiz Bir K\u0131lavuz<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The pathway to Investigational New Drug (IND) clearance for Duchenne muscular dystrophy is one of the most critical regulatory milestones in modern drug development. IND clearance allows experimental therapies\u2014ranging from gene therapies to exon-skipping drugs\u2014to move from laboratory research into human clinical trials. In the context of Duchenne muscular dystrophy (DMD), where unmet medical need [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7467,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[413,652,654,653,651],"class_list":["post-6340","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dmd","tag-dmd-clinical-trials","tag-fda-drug-approval","tag-fda-regulations","tag-ind-application-process","tag-ind-clearance"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=6340"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/7467"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=6340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=6340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=6340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}